GRK5 Inhibition Attenuates Cartilage Degradation via Decreased NF-κB Signalling.
NF-κB-dependent signalling is an important modulator in osteoarthritis (OA), and G protein-coupled receptor kinase 5 (GRK5) regulates the NF-κB pathway. This study investigated the functional involvement of GRK5 in OA pathogenesis. GRK5 expression in human normal and OA knee joints was analysed immunohistochemically. Gain- or loss-of-function experiments were performed using human and mouse chondrocytes. OA was induced in GRK5 knockout mice by destabilisation of the medial meniscus, followed by histological examination. Furthermore, OA was induced in wild-type mice, and then treated with an intra-articular injection of amlexanox, a selective GRK5 inhibitor, every 5 days for 8 weeks. GRK5 protein expression was increased in human OA cartilage. In vitro, expressions of OA-related factors and NF-κB transcriptional activation were down-regulated by GRK5 gene suppression in human OA chondrocytes (3.49-fold decrease in IL6, p < 0.01; 2.43-fold decrease in MMP13, p < 0.01; and 2.66-fold decrease in ADAMTS4; p < 0.01). Conversely, GRK5 overexpression significantly increased expressions of OA-related catabolic mediators and NF-κB transcriptional activation. On western blots, GRK5 deletion reduced IκBα phosphorylation (up to 4.4-fold decrease, p < 0.05) and decreased p65 nuclear translocation (up to 6.4-fold decrease, p < 0.01) in mouse chondrocytes. In vivo, both GRK5 deletion and intra-articular amlexanox injection protected mouse cartilage from OA. Our results suggest that GRK5 regulates cartilage degradation through a catabolic response mediated by NF-κB signalling, and is a potential target for OA treatment. Furthermore, amlexanox may be a major compound in relevant drugs.